Profund Advisors LLC Zentalis Pharmaceuticals, Inc. Transaction History

Profund Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$4.09 - $16.13 $63,435 - $250,176	-15,510 Reduced 33.43%	30,892 $126,000
Q1 2024 May 08, 2024	SELL	$10.83 - $16.49 $128,194 - $195,192	-11,837 Reduced 20.32%	46,402 $731,000
Q4 2023 Feb 14, 2024	BUY	$9.84 - $20.13 $236,779 - $484,388	24,063 Added 70.41%	58,239 $882,000
Q3 2023 Nov 13, 2023	SELL	$19.63 - $28.29 $222,898 - $321,232	-11,355 Reduced 24.94%	34,176 $685,000
Q2 2023 Aug 10, 2023	BUY	$17.41 - $30.05 $115,654 - $199,622	6,643 Added 17.08%	45,531 $1.28 Million
Q1 2023 May 11, 2023	BUY	$16.14 - $24.94 $627,652 - $969,866	38,888 New	38,888 $668,000

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Profund Advisors LLC with notifications on news.